These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11058787)

  • 1. Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity.
    Kuwabara T; Warashina M; Taira K
    Trends Biotechnol; 2000 Nov; 18(11):462-8. PubMed ID: 11058787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maxizyme technology.
    Iyo M; Kawasaki H; Taira K
    Methods Mol Biol; 2004; 252():257-65. PubMed ID: 15017055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosterically controllable maxizymes for molecular gene therapy.
    Iyo M; Kawasaki H; Taira K
    Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing of the secondary structure of maxizymes.
    Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
    Nucleic Acids Symp Ser; 1999; (42):219-20. PubMed ID: 10780458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T; Hamada M; Warashina M; Taira K
    Biomacromolecules; 2001; 2(3):788-99. PubMed ID: 11710033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M; Kuwabara T; Warashina M; Nakayama A; Taira K
    FEBS Lett; 1999 Nov; 461(1-2):77-85. PubMed ID: 10561500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maxizymes, novel allosterically controllable ribozymes, can be designed to cleave various substrates.
    Tanabe T; Takata I; Kuwabara T; Warashina M; Kawasaki H; Tani K; Ohta S; Asano S; Taira K
    Biomacromolecules; 2000; 1(1):108-17. PubMed ID: 11709832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Working at the cutting edge: the creation of allosteric ribozymes.
    Warashina M; Kuwabara T; Taira K
    Structure; 2000 Nov; 8(11):R207-12. PubMed ID: 11080644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cleavage of an inaccessible site by the maxizyme with two independent binding arms: an alternative approach to the recruitment of RNA helicases.
    Kuwabara T; Warashina M; Taira K
    J Biochem; 2002 Jul; 132(1):149-55. PubMed ID: 12097172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Mol Cell; 1998 Nov; 2(5):617-27. PubMed ID: 9844634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.
    Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
    J Inorg Biochem; 2000 Mar; 78(4):261-8. PubMed ID: 10857905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ; Yoon K; Moelling K; Coney LR
    Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P; Wright LA; Milliken S; Biggs JC
    Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
    James HA; Twomey CM; Mills KI; Gibson I
    Biochem Soc Trans; 1996 Aug; 24(3):409S. PubMed ID: 8878953
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W; Daskalakis M; Finke J; Dölken G
    FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
    Cobaleda C; Sánchez-García I
    Blood; 2000 Feb; 95(3):731-7. PubMed ID: 10648380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maxizymes and small hairpin-type RNAs that are driven by a tRNA promoter specifically cleave a chimeric gene associated with leukemia in vitro and in vivo.
    Oshima K; Kawasaki H; Soda Y; Tani K; Asano S; Taira K
    Cancer Res; 2003 Oct; 63(20):6809-14. PubMed ID: 14583478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTAB-mediated enrichment for active forms of novel dimeric maxizymes.
    Nakayama A; Kuwabara T; Warashina M; Taira K
    FEBS Lett; 1999 Apr; 448(1):67-74. PubMed ID: 10217412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.